Literature DB >> 28315782

Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

Oscar Solís1, Jose-Rubén García-Montes1, Patricia Garcia-Sanz1, Antonio S Herranz2, Maria-José Asensio2, Gina Kang3, Noboru Hiroi3, Rosario Moratalla4.   

Abstract

Catechol-O-methyltransferase (COMT) degrades dopamine and its precursor l-DOPA and plays a critical role in regulating synaptic dopamine actions. We investigated the effects of heightened levels of COMT on dopamine-regulated motor behaviors and molecular alterations in a mouse model of dyskinesia. Transgenic mice overexpressing human COMT (TG) and their wildtype (WT) littermates received unilateral 6-OHDA lesions in the dorsal striatum and were treated chronically with l-DOPA for two weeks. l-DOPA-induced dyskinesia was exacerbated in TG mice without altering l-DOPA motor efficacy as determined by contralateral rotations or motor coordination. Inductions of FosB and phospho-acetylated histone 3 (molecular correlates of dyskinesia) were potentiated in the lesioned striatum of TG mice compared with their WT littermates. The TG mice had lower basal levels of dopamine in the striatum. In mice with lesions, l-DOPA induces a greater increase in the dopamine metabolite 3-methoxytyramine in the lesioned striatum of dyskinetic TG mice than in WT mice. The levels of serotonin and its metabolite were similar in TG and WT mice. Our results demonstrate that human COMT overexpression confers a heightened susceptibility to l-DOPA-induced dyskinesia and alters molecular and neurochemical responses in the lesioned striatum of mice.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  22q11.2; ARVCF; Abnormal involuntary movements; COMT; Dopamine; LID; Striatum; TXNRD2; l-DOPA

Mesh:

Substances:

Year:  2017        PMID: 28315782      PMCID: PMC5481205          DOI: 10.1016/j.nbd.2017.03.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  44 in total

1.  L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.

Authors:  W Q Zhao; L Latinwo; X X Liu; E S Lee; N Lamango; C G Charlton
Journal:  Exp Neurol       Date:  2001-09       Impact factor: 5.330

Review 2.  The catechol-O-methyltransferase gene: its regulation and polymorphisms.

Authors:  Elizabeth M Tunbridge
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

Review 3.  Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.

Authors:  Concepció Marin; J A Obeso
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

4.  Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.

Authors:  Irene Ruiz-DeDiego; Britt Mellstrom; Mario Vallejo; Jose R Naranjo; Rosario Moratalla
Journal:  Biol Psychiatry       Date:  2014-03-27       Impact factor: 13.382

Review 5.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

6.  Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.

Authors:  Manuela Contin; Paolo Martinelli; Mirella Mochi; Roberto Riva; Fiorenzo Albani; Agostino Baruzzi
Journal:  Mov Disord       Date:  2005-06       Impact factor: 10.338

7.  Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.

Authors:  M Watanabe; S Harada; T Nakamura; N Ohkoshi; K Yoshizawa; A Hayashi; S Shoji
Journal:  Neuropsychobiology       Date:  2003       Impact factor: 2.328

8.  Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

Authors:  Jenny E Westin; Linda Vercammen; Elissa M Strome; Christine Konradi; M Angela Cenci
Journal:  Biol Psychiatry       Date:  2007-07-26       Impact factor: 13.382

9.  Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia.

Authors:  Amandine Berthet; Grégory Porras; Evelyne Doudnikoff; Holger Stark; Martine Cador; Erwan Bezard; Bertrand Bloch
Journal:  J Neurosci       Date:  2009-04-15       Impact factor: 6.167

10.  L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.

Authors:  Luz M Suarez; Oscar Solis; Carolina Aguado; Rafael Lujan; Rosario Moratalla
Journal:  Cereb Cortex       Date:  2016-10-17       Impact factor: 5.357

View more
  10 in total

1.  Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP+ Toxicity In Vivo.

Authors:  Natalia Moreno-Galarza; Liliana Mendieta; Victoria Palafox-Sánchez; Mireia Herrando-Grabulosa; Carles Gil; Daniel I Limón; José Aguilera
Journal:  Neurotox Res       Date:  2018-02-19       Impact factor: 3.911

2.  Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.

Authors:  José-Rubén García-Montes; Oscar Solís; Juan Enríquez-Traba; Irene Ruiz-DeDiego; René Drucker-Colín; Rosario Moratalla
Journal:  Mol Neurobiol       Date:  2018-09-27       Impact factor: 5.590

Review 3.  Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia.

Authors:  Oscar Solís; Rosario Moratalla
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

4.  Striatal Reinnervation Process after Acute Methamphetamine-Induced Dopaminergic Degeneration in Mice.

Authors:  Noelia Granado; Sara Ares-Santos; Yousef Tizabi; Rosario Moratalla
Journal:  Neurotox Res       Date:  2018-06-22       Impact factor: 3.911

5.  Effort-related decision making in humanized COMT mice: Effects of Val158Met polymorphisms and possible implications for negative symptoms in humans.

Authors:  Jen-Hau Yang; Rose E Presby; Suzanne Cayer; Renee A Rotolo; Peter A Perrino; R Holly Fitch; Merce Correa; Elissa J Chesler; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2020-06-25       Impact factor: 3.697

6.  RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.

Authors:  Mehdi Eshraghi; Uri Nimrod Ramírez-Jarquín; Neelam Shahani; Tommaso Nuzzo; Arianna De Rosa; Supriya Swarnkar; Nicole Galli; Oscar Rivera; George Tsaprailis; Catherina Scharager-Tapia; Gogce Crynen; Qin Li; Marie-Laure Thiolat; Erwan Bezard; Alessandro Usiello; Srinivasa Subramaniam
Journal:  Sci Adv       Date:  2020-05-01       Impact factor: 14.136

7.  Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice.

Authors:  Iara Pérez-Taboada; Samuel Alberquilla; Eduardo D Martín; Rishi Anand; Stefania Vietti-Michelina; Nchimunya N Tebeka; James Cantley; Stephanie J Cragg; Rosario Moratalla; Mario Vallejo
Journal:  Mov Disord       Date:  2020-07-15       Impact factor: 10.338

8.  Network Pharmacology and Metabolomics Studies on Antimigraine Mechanisms of Da Chuan Xiong Fang (DCXF).

Authors:  Shiyu Ma; Lin Zheng; Xiao Lin; Yi Feng; Ming Yang; Lan Shen
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-20       Impact factor: 2.629

Review 9.  Levodopa treatment and dendritic spine pathology.

Authors:  Haruo Nishijima; Tatsuya Ueno; Yukihisa Funamizu; Shinya Ueno; Masahiko Tomiyama
Journal:  Mov Disord       Date:  2017-09-07       Impact factor: 10.338

Review 10.  L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.

Authors:  Abdeslam Chagraoui; Marie Boulain; Laurent Juvin; Youssef Anouar; Grégory Barrière; Philippe De Deurwaerdère
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.